Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neugcgm3 + vssp
- Development stage
- Unknown
- Lead developer
- Center for Molecular Immunology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
NeuGcGM3 + VSSP is a cancer vaccine composed of the ganglioside NeuGcGM3 (N-glycolylneuraminic acid-containing GM3) combined with very small size proteoliposomes (VSSP), which are derived from the outer membrane protein complex of Neisseria meningitidis. The vaccine is typically formulated with an adjuvant such as Montanide ISA 51 to enhance immunogenicity. It is designed to induce an immune response against tumor cells expressing the NeuGcGM3 ganglioside, which is found on certain cancers but not in normal human tissues due to a genetic difference in sialic acid metabolism[1][4][6]. The mechanism involves stimulating both humoral and cellular immune responses, leading to antibody production and complement-mediated cytotoxicity against tumor cells[1][4].
- Brand names
- CIMAVaxG vaccine
- Other names
- NeuGcGM3-VSSPNeuGcGM-3-VSSPNeuGcGM 3-VSSPNGcGM3-VSSPNGcGM-3-VSSPNGcGM 3-VSSPheterophilic ganglioside cancer vaccine
02
Targets
NeuGcGM3 (N-glycolyl-GM3 ganglioside)
Beyond the preview
Go deeper on neugcgm3 + vssp.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neugcgm3 + vssp.